Gleiss Lutz advises Sulzer AG on the acquisition of medical technology company Haselmeier

Gleiss Lutz and Swiss law firm Walder Wyss have together advised Sulzer AG on its acquisition of the Haselmeier Group. The transaction is expected to close in the fourth quarter of 2020.

Haselmeier is a leading developer and manufacturer of drug delivery systems, such as pen injectors for the self-administration of drugs for the treatment of fertility problems, growth disorders, osteoporosis and diabetes. The company has a staff of 230 and generated EUR 36 million in turnover in 2019.

The purchase, with a volume of EUR 100 million, sees Sulzer enlarging its healthcare portfolio.

Listed on the Swiss stock exchange, Sulzer AG is a global leader in fluid engineering, specialising in pumping, agitation, mixing, separation and application technologies for fluids of all types. With around 180 manufacturing facilities and service centres across the globe, Sulzer generated a turnover of CHF 3.7 billion in 2019.

The following Gleiss Lutz team advised Sulzer AG on the transaction: Dr. Ralf Morshäuser (partner, lead), Dr. Tobias Falkner (counsel), Melina Grauschopf, Dr. Stephanie Dausinger (all M&A, Munich), Dr. Enno Burk (counsel, healthcare), Dr. Alexander Molle (partner, IP/IT/commercial, Berlin), Jan Hinrichs (commercial, Berlin), Karen Gräfin vom Hagen (commercial, Stuttgart), Dr. Doris-Maria Schuster (partner, Hamburg), Dr. Daniela Mayr (Munich, both employment), Dr. Jacob von Andreae (partner), Aylin Hoffs (both public law, Düsseldorf), Dr. Ulrich Denzel (partner), Patrick Grüner (counsel, both competition/antitrust, Stuttgart).

A team from Walder Wyss headed by Markus Vischer advised on the Swiss law aspects of the transaction.